167 related articles for article (PubMed ID: 24722669)
1. A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs.
Gao Q; Chen C; Ji T; Wu P; Han Z; Fang H; Li F; Liu Y; Hu W; Gong D; Zhang Z; Wang S; Zhou J; Ma D
PLoS One; 2014; 9(4):e94050. PubMed ID: 24722669
[TBL] [Abstract][Full Text] [Related]
2. Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs.
Chen C; Fang H; Han Z; Ye F; Ji T; Gong D; Li F; Zhou J; Ma D; Gao Q
Gene Ther; 2014 Nov; 21(11):975-83. PubMed ID: 25185643
[TBL] [Abstract][Full Text] [Related]
3. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.
Wold WS; Toth K
Adv Cancer Res; 2012; 115():69-92. PubMed ID: 23021242
[TBL] [Abstract][Full Text] [Related]
4. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration.
Tong XW; Block A; Chen SH; Contant CF; Agoulnik I; Blankenburg K; Kaufman RH; Woo SL; Kieback DG
Gynecol Oncol; 1996 May; 61(2):175-9. PubMed ID: 8626129
[TBL] [Abstract][Full Text] [Related]
5. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.
Rodríguez-García A; Giménez-Alejandre M; Rojas JJ; Moreno R; Bazan-Peregrino M; Cascalló M; Alemany R
Clin Cancer Res; 2015 Mar; 21(6):1406-18. PubMed ID: 25391696
[TBL] [Abstract][Full Text] [Related]
7. Cloning of carrier cells infected with oncolytic adenovirus driven by midkine promoter and biosafety studies.
Hamada K; Takagi S; Kuboshima H; Shimada H; Takagi K; Yasuoka T; Matsubara K; Sassa Y; Furuya T; Suzuki K; Uchide T; Mizutani T; Tani K; Itoh H; Sugiyama T
J Gene Med; 2019 Feb; 21(2-3):e3064. PubMed ID: 30548997
[TBL] [Abstract][Full Text] [Related]
8. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
Dhar D; Toth K; Wold WS
Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
[TBL] [Abstract][Full Text] [Related]
9. Imaging of viral thymidine kinase gene expression by replicating oncolytic adenovirus and prediction of therapeutic efficacy.
Kim EJ; Yoo JY; Choi YH; Ahn KJ; Lee JD; Yun CO; Yun M
Yonsei Med J; 2008 Oct; 49(5):811-8. PubMed ID: 18972602
[TBL] [Abstract][Full Text] [Related]
10. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
11. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
12. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.
Dhar D; Toth K; Wold WS
Cancer Gene Ther; 2014 Apr; 21(4):171-8. PubMed ID: 24722357
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
[TBL] [Abstract][Full Text] [Related]
14. Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models.
Zheng FQ; Xu Y; Yang RJ; Wu B; Tan XH; Qin YD; Zhang QW
Acta Pharmacol Sin; 2009 May; 30(5):617-27. PubMed ID: 19363518
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
16. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo.
Zhang JF; Wei F; Wang HP; Li HM; Qiu W; Ren PK; Chen XF; Huang Q
J Exp Clin Cancer Res; 2010 May; 29(1):52. PubMed ID: 20487549
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated thymidine kinase gene therapy induces apoptosis in human epithelial ovarian cancer cells and damages PARP-1.
Kieback DG
In Vivo; 2009; 23(1):77-80. PubMed ID: 19368128
[TBL] [Abstract][Full Text] [Related]
19. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated suicide gene therapy for experimental bladder cancer.
Sutton MA; Berkman SA; Chen SH; Block A; Dang TD; Kattan MW; Wheeler TM; Rowley DR; Woo SL; Lerner SP
Urology; 1997 Feb; 49(2):173-80. PubMed ID: 9037277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
